This article will highlight the latest list of cancer pipeline drugs, specifically focussed on breast cancer pipeline drugs, pharmaceutical companies of researching breast cancer drugs, drug target of breast cancer, drug type of breast cancer and countries/locations of researching breast cancer drugs.
Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.
This study first revealed that dexmedetomidine inhibits the microglial synaptic elimination process mediated by the complement C3-C3aR signaling pathway.
Synapse functions as an indispensable free drug pipeline database tool for pharmaceutical and biotech sectors, enhancing drug pipelines and marketed drugs by presenting analytical intelligence on a wide range of drug discovery and development.
Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.
The study, titled "Netrin-1 blockade inhibits tumor growth and EMT features in endometrial cancer," presents compelling evidence of the efficacy of a novel anti-Netrin-1 antibody in reducing tumor progression and inhibiting epithelial-to-mesenchymal transition (EMT).
AMPK, which stands for AMP-activated protein kinase, is a key molecule in regulating energy metabolism and is at the core of research into diabetes and other metabolic-related diseases.